Curevac AG-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Curevac AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013942
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Curevac AG (Curevac), formerly CureVac GmbH is a clinical stage biopharmaceutical company that develops RNA-based medicines. The company designs, develops and produces messenger RNA molecules for therapeutic and prophylactic vaccines in the fields of oncology and infectious diseases. Its RNA technology platforms include RNAntibody, RNArt, RNActive, and RNAdjuvant. Curevac’s RNActive technology is used to develop treatments against cancer and prophylactic vaccines for infectious diseases. The company’s RNAdjuvant technology is used to enhance the immune response of other vaccines. Its products are used in the treatment of prostate cancer and non-small cell lung cancer; and infectious diseases such as rabies, rotavirus, influenza, and other undisclosed. The company program the RNA molecule to address a specific medical need. It operates through pharmaceutical companies and research institutes. CureVac is headquartered in Tubingen, Germany.

Curevac AG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Curevac AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Curevac AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Curevac AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Curevac AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Curevac AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Curevac AG, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
CureVac to Raise USD76 Million in Venture Financing 10
CureVac Raises US$105 Million In Series D Financing 11
Partnerships 12
Eli Lilly and CureVac Enter into Partnership 12
International AIDS Vaccine Partners with CureVac 13
CureVac to Enter into Development Agreement with Bill & Melinda Gates 14
Crucell Vaccine Enters Into Co-Development Agreement With CureVac For Respiratory Vaccine 15
CureVac Enters Into Co-Development Agreement With Sanofi Pasteur 16
Licensing Agreements 17
CRISPR and Casebia Receive Rights to the Improved Constructs from Curevac 17
Boehringer Ingelheim Enters into Licensing Agreement with CureVac for CV9202 18
CureVac Enters into Licensing Agreement with Sanofi Pasteur to Develop mRNA-Based Prophylactic Vaccine 20
Equity Offering 21
CureVac Raises Additional USD29.5 Million in Private Placement 21
CureVac Raises USD110 Million in Private Placement of Shares 22
Curevac AG – Key Competitors 23
Curevac AG – Key Employees 24
Curevac AG – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Strategy And Business Planning 26
Oct 30, 2017: CureVac Announces Groundbreaking of Industrial-Scale GMP Production Facility for RNA Therapeutics 26
Corporate Communications 27
Oct 11, 2016: CureVac Appoints Pierre Kemula as Chief Financial Officer 27
Mar 18, 2016: CureVac strengthens supervisory board to support global growth opportunities and mRNA product expansion 28
Government and Public Interest 29
Feb 18, 2016: CureVac announces “MERAN” has been approved by the WHO as suffix for mRNA drug substances 29
Product News 30
Oct 23, 2017: Publication in npj Vaccines Demonstrates CureVac’s RNActive Vaccine is Superior to Licensed Vaccines 30
Clinical Trials 31
Dec 05, 2016: Study with CureVac’s RNAdjuvant Technology Published in Cancer Immunology, Immunotherapy, Demonstrates Equal responsiveness of blood cells from Both Hepatocellular Carcinoma Patients and Healthy Subjects to the RNA-based adjuvant 31
Other Significant Developments 32
Jun 26, 2017: CureVac Expands GMP Production Capacities for RNA Products 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Curevac AG, Pharmaceuticals & Healthcare, Key Facts 2
Curevac AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Curevac AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Curevac AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Curevac AG, Deals By Therapy Area, 2011 to YTD 2017 8
Curevac AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
CureVac to Raise USD76 Million in Venture Financing 10
CureVac Raises US$105 Million In Series D Financing 11
Eli Lilly and CureVac Enter into Partnership 12
International AIDS Vaccine Partners with CureVac 13
CureVac to Enter into Development Agreement with Bill & Melinda Gates 14
Crucell Vaccine Enters Into Co-Development Agreement With CureVac For Respiratory Vaccine 15
CureVac Enters Into Co-Development Agreement With Sanofi Pasteur 16
CRISPR and Casebia Receive Rights to the Improved Constructs from Curevac 17
Boehringer Ingelheim Enters into Licensing Agreement with CureVac for CV9202 18
CureVac Enters into Licensing Agreement with Sanofi Pasteur to Develop mRNA-Based Prophylactic Vaccine 20
CureVac Raises Additional USD29.5 Million in Private Placement 21
CureVac Raises USD110 Million in Private Placement of Shares 22
Curevac AG, Key Competitors 23
Curevac AG, Key Employees 24
Curevac AG, Other Locations 25
Curevac AG, Subsidiaries 25

★海外企業調査レポート[Curevac AG-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • 7-Eleven Inc:企業の戦略的SWOT分析
    7-Eleven Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • GEN energija, d.o.o.:企業の戦略的SWOT分析
    GEN energija, d.o.o. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Universal Biosensors Inc (UBI)-医療機器分野:企業M&A・提携分析
    Summary Universal Biosensors Inc (UBI) is a medical diagnostic company. The company researches, develops and manufactures in vitro diagnostic test devices that are used for professional and consumer point-of-care. The company is working with Siemens Healthcare to develop a range of products for the …
  • Ambry Genetics Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Ambry Genetics Corp (Ambry Genetics), a subsidiary of Konica Minolta Inc, is a provider of clinical genetic testing services. The company provides genetic diagnosis for various conditions including hereditary cancer, epilepsy, hereditary cardiovascular disease and neurodevelopmental disorder …
  • Peco Energy Company:電力:M&Aディール及び事業提携情報
    Summary PECO Energy Company (PECO), a subsidiary of Exelon Corporation, is a public utility that purchases and sells electricity and gas, and provides electricity transmission and distribution, and gas distribution services. It supplies electricity and gas to residential, commercial, and industrial …
  • J.E. Dunn Construction Group Inc:企業の戦略的SWOT分析
    J.E. Dunn Construction Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • CG Power and Industrial Solutions Ltd (CGPOWER):企業の財務・戦略的SWOT分析
    CG Power and Industrial Solutions Ltd (CGPOWER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • United States Postal Service:企業の戦略的SWOT分析
    United States Postal Service - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Macquarie Group Ltd
    Macquarie Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Macquarie Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Aclaris Therapeutics Inc (ACRS):製薬・医療:M&Aディール及び事業提携情報
    Summary Aclaris Therapeutics Inc (Aclaris Therapeutics) is a dermatologist-led bio-pharmaceutical company which focuses on identifying, developing, and commercializing prescription drug products for unmet needs in aesthetic and medical dermatology as well as immunology. Its lead product, ESKATA, is …
  • DS Smith Plc:企業のM&A・事業提携・投資動向
    DS Smith Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's DS Smith Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Minor International PCL:企業の戦略・SWOT・財務情報
    Minor International PCL - Strategy, SWOT and Corporate Finance Report Summary Minor International PCL - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Chemring Energetics UK Ltd:企業の戦略・SWOT・財務情報
    Chemring Energetics UK Ltd - Strategy, SWOT and Corporate Finance Report Summary Chemring Energetics UK Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Brixmor Property Group Inc:企業の戦略・SWOT・財務情報
    Brixmor Property Group Inc - Strategy, SWOT and Corporate Finance Report Summary Brixmor Property Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Acino International AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Acino International AG (Acino), formerly Acino Holding AG, manufactures and commercializes generic and prescription pharmaceuticals in novel drug delivery forms. The company focuses on the therapeutic areas of oncology, cardiology and metabolism, central nervous system, gastroenterology, inf …
  • FBD Holdings Plc (EG7):企業の財務・戦略的SWOT分析
    FBD Holdings Plc (EG7) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Maersk Line AS:企業の戦略的SWOT分析
    Maersk Line AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Future Consumer Ltd (FCONSUMER):企業の財務・戦略的SWOT分析
    Future Consumer Ltd (FCONSUMER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Aggreko Plc (AGK):企業の戦略的SWOT分析
    Aggreko Plc (AGK) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Jones Lang LaSalle Inc (JLL):企業の財務・戦略的SWOT分析
    Jones Lang LaSalle Inc (JLL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆